ATRC
A bigger slice of AtriCure
Massachusetts Financial Services Co. MA boosted its position in AtriCure by 20.4%, lifting its stake to 511,213 shares, or roughly 1.03% of the company. At current values, that’s about $20.2 million parked in the medical-device maker.
Why you should care
Institutional buying doesn’t always mean fireworks tomorrow morning, but it can matter. When a big fund adds to a name, it’s basically saying, “We still like this story,” and other investors tend to notice when that story involves a company with a $1.49 billion market cap and a stock that’s been doing the usual small-cap heart-rate monitor thing.
Not just one fund nibbling
MFS wasn’t alone. Wellington and Kennedy also increased their holdings, which pushed institutional ownership to 99.11%. That’s a pretty crowded club, and it suggests the smart-money crowd is still hanging around AtriCure rather than heading for the exits.
The side quest: analyst optimism
The article also notes that analysts remain constructive on ATRC, with a consensus "Moderate Buy" rating and an average price target of $48.43 versus a recent share price near $29.37. The company also recently beat EPS estimates, posting $0.06 instead of the expected -$0.04, while revenue rose 13.1% year over year.
Big picture: this isn’t a dramatic catalyst, but it’s another signal that the market’s more serious adults still see upside in AtriCure — even if the stock itself hasn’t exactly been throwing a victory parade.